The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression
Open accessAbstract
Mesenchymal stem cells (MSCs) can exhibit a marked tropism towards site of tumors. Many studies have reported that tumor progression and metastasis increase by MSCs. In contrast, other studies have shown that MSCs suppress growth of tumors. MSCs contribute to tumor growth promotion by several mechanisms: (1) transition to tumor-associated fibroblasts; (2) suppression of immune response; (3) promotion of angiogenesis; (4) stimulation of epithelial-mesenchymal transition (EMT); (5) contribution to the tumor microenvironment; (6) inhibition of tumor cell apoptosis; and (7) promotion of tumor metastasis. In contrast to the tumor-promoting properties, MSCs inhibit tumor growth by increasing inflammatory infiltration, inhibiting angiogenesis, suppressing Wnt signaling and AKT signaling, and inducing cell cycle arrest and apoptosis. In this review, we will discuss potential mechanisms by which MSC mediates tumor support or suppression and then the possible tumor-specific therapeutic strategies using MSCs as delivery vehicles, based on their homing potential to tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151
RetractedDasari, V. R., Velpula, K. K., Kaur, K., Fassett, D., Klopfenstein, J. D., Dinh, D. H., Gujrati, M., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011813 · Cited by 87 · cited 1×
“reported that downregulation of the anti-apoptotic inhibitor, X-linked inhibitor of apoptosis protein (XIAP), by human umbilical cord blood-derived mesenchymal stem cell (hUCBSC) treatment induced apoptosis of glioma cells and xenograft cells through the activation of caspase-3 and caspase-9 [45,46].”
BackgroundRetractedDominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“In the tumor microenvironment, the tumor attempts to avoid recognition by the immune system while simultaneously secreting inflammatory mediators to establish and maintain a constant state of inflammation [32].”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183 · cited 1×
“The WNT signaling pathway has also been associated with the development of carcinomas of the breast, liver, colon, skin, stomach, and ovary [160–171].”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“Furthermore, PGE2 increases the expression level of anti-inflammatory cytokine IL-10 and decreases expression of TNF-α, IFN-γ, and IL-12 in dendritic cells (DCs) and macrophages [89,90].”
BackgroundBissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Kinnaird, T., Stabile, E., Burnett, M. S., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004) · Circulation Research · doi:10.1161/01.res.0000118601.37875.ac · Cited by 1,415 · cited 1×
“These molecules induce angiogenesis of endothelial cells synergistically [100].”
BackgroundComparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow
De Ugarte, D. A., Morizono, K., Elbarbary, A., Alfonso, Z., Zuk, P. A., Zhu, M., Dragoo, J. L., Ashjian, P., Thomas, B., Benhaim, P., et al. (2003) · Cells Tissues Organs · doi:10.1159/000071150 · Cited by 1,173
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“Furthermore, allogeneic mice transplanted with B16 melanoma cells did not support tumor formation in the absence of concomitant MSC co-injection [56].”
BackgroundInteractions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956 · cited 1×
“MSCs secrete a variety of cytokines that induce cell cycle arrest of tumor cells, albeit transiently, at the G1 phase through expression of CyclinA, CyclinE, CyclinD2, and p27KIP1 [44,145,149–153].”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Polakis, P. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008052 · Cited by 847
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620 · cited 1×
“The phosphoinositide 3-kinase (PI3K)/AKT and WNT/β-catenin signaling pathway controls cell survival, proliferation, growth, migration, and metabolism [154–159].”
BackgroundSpecies Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Hung, S.-C., Pochampally, R. R., Chen, S.-C., Hsu, S.-C., & Prockop, D. J. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0686 · Cited by 457 · cited 1×
“Moreover, under hypoxic and starved conditions, MSCs can survive via autophagy and release many anti-apoptotic or pro-survival factors, such as VEGF, FGF-2, PDGF, HGF, brain-derived neurotropic factor (BDNF), SDF-1α, IGF-1 and IGF-2, transforming growth factor-β (TGF-β), and IGF binding protein-2 (IGFBP-2) [28,134–138…”
BackgroundAdipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 2×
“Numerous studies have used MSCs engineered to express and deliver a variety of anti-cancer drugs, such as type I interferon (IFN-α and IFN-β), IL-12, IL-2, CXCL1, oncolytic virus, cytokine deaminase, nanoparticles, and TRAIL [50,172,173,176,188–202].”
BackgroundMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Ramasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380 · cited 1×
“These results imply that MSCs can promote tumor growth by increasing the CSC number through BMP expression [128].”
BackgroundKidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., & Marini, F. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030563 · Cited by 371 · cited 1×
“By contrast, it has been reported that different MSCs isolated from two distinct tissues can be recruited into tumor microenvironments, and the different MSC types can be more prompt to transdifferentiate into determined cell types [10].”
BackgroundQiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302
Zacharek, A., Chen, J., Li, A., Cui, X., Li, Y., Roberts, C., Feng, Y., Gao, Q., & Chopp, M. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600475 · Cited by 297
Martin, F. T., Dwyer, R. M., Kelly, J., Khan, S., Murphy, J. M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F. P., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0734-1 · Cited by 290 · cited 2×
“When breast cancer cells were co-incubated with human MSCs, the expression of oncogenes and proto-oncogenes was upregulated in breast cancer cells [116].”
BackgroundChen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283
Cannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239
Tumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230 · cited 1×
“In contrast, TAMs can show antitumor activities linked to the M1 phenotype via IFN-γ, TNF-α, TGF-β, PGE2, and IL-10 [72,77–82].”
BackgroundThe growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo
Lu, Y.-R., Yuan, Y., Wang, X.-J., Wei, L.-L., Chen, Y.-N., Cong, C., Li, S.-F., Long, D., Tan, W.-D., Mao, Y.-Q., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5296 · Cited by 225
Xu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V., & Altaner, C. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1239 · Cited by 171
Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells
Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007) · STEM CELLS · doi:10.1634/stemcells.2006-0461 · Cited by 164 · cited 1×
“activate both T cells and NK cells, and result in a substantial decrease in lung and breast tumors and melanoma [175,191,193,195,204].”
BackgroundPinilla, S., Alt, E., Abdul Khalek, F. J., Jotzu, C., Muehlberg, F., Beckmann, C., & Song, Y.-H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.013 · Cited by 156 · cited 1×
“CCL5/RANTES-mediated invasion is also closely related with increased activity of matrix metalloproteinase 9 (MMP-9) [38].”
BackgroundJansen, B. J. H., Gilissen, C., Roelofs, H., Schaap-Oziemlak, A., Veltman, J. A., Raymakers, R. A. P., Jansen, J. H., Kögler, G., Figdor, C. G., Torensma, R., et al. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0288 · Cited by 139
Berniakovich, I., & Giorgio, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14012119 · Cited by 103 · cited 1×
“Additionally, the expression of Rex-1 and Oct-4 was increased, leading to the conclusion that MSC stemness was increased during hypoxia [133].”
BackgroundHonoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90
Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy
Eliopoulos, N., Francois, M., Boivin, M.-N., Martineau, D., & Galipeau, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0160 · Cited by 90 · cited 1×
“activate both T cells and NK cells, and result in a substantial decrease in lung and breast tumors and melanoma [175,191,193,195,204].”
BackgroundDu, J., Zhou, L., Chen, X., Yan, S., Ke, M., Lu, X., Wang, Z., Yu, W., & Xiang, A. P. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.015 · Cited by 41 · cited 1×
“Moreover, MSCs primed with IFN-γ or cultured with tri-dimensional systems can express TRAIL, which induces tumor cell-specific apoptosis [132,147].”
Background
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Samsonraj, R. M., Raghunath, M., Nurcombe, V., Hui, J. H., van Wijnen, A. J., & Cool, S. M. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0129 · Cited by 729
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., Vega, B., Schneider, J., & Vizoso, F. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03600-0 · Cited by 313
Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles
Park, K.-S., Bandeira, E., Shelke, G. V., Lässer, C., & Lötvall, J. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1398-3 · Cited by 256
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Metadata
- Authors
- Rhee, K.-J., Lee, J., & Eom, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-12-16
- Volume
- 16
- Issue
- 12
- Pages
- 30015-30033
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2202177797
- Cited by
- 214
- References
- 58
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.